U.S. Logistics Stock News

Empire State Realty OP (ESBA) just wrapped up FY 2025 with Q4 total revenue of US$199.7 million and basic EPS of US$0.13, while trailing twelve month revenue sits at US$768.3 million and EPS at US$0.27. Over the past few quarters, revenue has moved from US$197.6 million in Q4 2024 to US$199.7 million in Q4 2025, with quarterly EPS shifting from US$0.07 to US$0.13. This sets up a picture where investors will be weighing these earnings against a 9.5% net margin and the impact of a one off gain...

Wix.com (WIX) is back in focus as investors position ahead of its March 4 earnings release, while the company rolls out new AI powered tools and integrations with Google and Intuit that aim to deepen its role in online commerce. See our latest analysis for Wix.com. With the share price at US$72.56, Wix.com has seen a 2.98% 1 day share price return and a 15.54% 7 day share price return, but a 24.31% 90 day share price decline and a 61.68% 1 year total shareholder return decline suggest...

Investors may be wondering whether Kroger, at around its recent US$69.05 close, is still a reasonable entry point or if most of the easy value is already on the table. The stock has returned 1.2% over the last 7 days, 9.9% over the past month, 9.7% year to date, 12.0% over 1 year, 58.7% over 3 years and 121.0% over 5 years. These returns may have shifted how the market views its risk and return trade off. Recent coverage has focused on Kroger's ongoing position as a major US grocery chain...

In recent months, Progressive reported higher net premiums written and earned, stronger underwriting margins with an improved combined ratio, and broad policy growth across personal, commercial, and property lines. An interesting angle is how its push into digital and direct-to-consumer channels appears to be amplifying this operational momentum across the entire franchise. Next, we’ll examine how this improved combined ratio and premium growth may influence Progressive’s existing investment...

Activist pressure puts ASA Gold and Precious Metals in focus Saba Capital Management LP has urged ASA Gold and Precious Metals (ASA) to conduct a comprehensive review, with an updated February 19 presentation outlining clarified alternatives for the Board to evaluate. For you as an investor, this kind of activist communication often raises questions around portfolio structure, capital allocation and potential changes that could affect how ASA trades relative to its underlying precious metals...

If you are wondering whether MetLife’s current share price reflects its true worth, this article explains how the market might be pricing the stock today. MetLife last closed at US$73.24, with returns of a 2.7% decline over 7 days, a 7.2% decline over 30 days, an 8.8% decline year to date, and a 12.0% decline over 1 year, compared with gains of 15.3% over 3 years and 41.2% over 5 years. These mixed returns sit against a backdrop of ongoing news coverage around the company’s position as a...

In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome workflow and expanded Illumina Laboratory Services to support Florida State University’s new pediatric rare disease diagnostic lab with clinical sequencing and interpretation. Together, these moves pair higher‑resolution sequencing technology with real‑world clinical deployment, underscoring Illumina’s push to make advanced rare disease diagnostics more accessible and operationally efficient for hospitals and...

Roku (ROKU) just followed up a stronger fourth quarter with a slot at Bernstein’s “What’s next in tech?” forum, giving investors fresh context on its earnings, platform reach, and position as a neutral streaming aggregator. See our latest analysis for Roku. Roku’s recent 16.2% 7 day share price return and 22.2% 1 year total shareholder return sit against a weaker year to date share price return of 9.8% decline, suggesting momentum has picked up again around its earnings and platform...

Nuvation Bio (NUVB) just finalized a protocol amendment that advances its global SIGMA safusidenib study into Phase 3, widening access for high risk IDH1 mutant astrocytoma patients and drawing additional investor attention to upcoming earnings. See our latest analysis for Nuvation Bio. The share price, now at US$5.84, has a 7 day share price return of 7% and a 30 day share price return of 11%, but a 90 day share price return of a 22% decline. The 1 year total shareholder return is over 3x...

UroGen Pharma FY 2025 results set the stage for growth versus losses debate UroGen Pharma (URGN) closed out FY 2025 with Q4 revenue of US$37.8 million and a basic EPS loss of US$0.54, alongside a trailing twelve month loss of US$3.19 per share on US$109.8 million of revenue. The company has seen quarterly revenue move from US$24.6 million in Q4 2024 to US$37.8 million in Q4 2025. Over the same period, basic EPS ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.54 in the latest...

Interactive Brokers Group (NasdaqGS:IBKR) reports strong growth in client activity and trading volumes. The broker launches stablecoin funding for U.S. clients, allowing deposits in certain digital dollar tokens. The company highlights continued progress in brokerage technology and its inclusion in the S&P 500 Index. Interactive Brokers Group, trading at around $71.67, sits in a very different place than it did a few years ago, with a 1 year return of 43.0% and a 5 year return of 288.5%...

Immunome, Inc. recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, updating investors on its oncology-focused pipeline and regulatory plans. A key highlight is the company’s push toward a New Drug Application for Varegacestat in desmoid tumors, alongside multiple upcoming solid tumor IND submissions and an FDA-cleared radioligand therapy trial. We’ll now examine how Immunome’s renewed oncology focus and advancing Varegacestat program might influence the company’s...

If you are wondering whether Bunge Global’s current share price lines up with its underlying worth, this article walks through the key numbers that matter for valuation. The stock recently closed at US$120.61, after a 0.6% decline over 7 days, a 5.9% gain over 30 days, and returns of 30.2% year to date, 73.1% over 1 year, 34.3% over 3 years, and 75.8% over 5 years. Recent coverage has focused on Bunge Global’s role in global agribusiness and food supply chains and how that positioning may...

Why Fresh Del Monte Produce (FDP) is back in focus Fresh Del Monte Produce (FDP) just reported fourth quarter and full year 2025 results, along with a fresh dividend declaration and an update on its completed share buyback. This gives investors several moving parts to assess at once. See our latest analysis for Fresh Del Monte Produce. The recent update on earnings, dividends and buybacks comes after a strong run in the share price, with a 16.84% 3 month share price return and a 47.18% 1 year...

Cullen/Frost Bankers (CFR) has drawn fresh attention after recent trading, with the share price closing at $140.21 and posting mixed short term returns while still showing gains over the past 3 months and year. See our latest analysis for Cullen/Frost Bankers. The recent 1 day share price return of 1.44% sits against a 7 day share price return of negative 1.35%. At the same time, the 90 day share price return of 13.93% and 1 year total shareholder return of 7.14% point to momentum that has...

Apogee Therapeutics reported a full-year net loss of US$255.84 million for 2025, with basic and diluted loss per share of US$4.22 as it continued to report no product revenue while investing heavily in its antibody pipeline. Alongside deeper losses, the company underscored upcoming clinical milestones for zumilokibart and other programs and filed a US$287.29 million shelf registration tied to an employee stock ownership plan, highlighting both capital needs and efforts to align employee...

ImmunityBio (IBRX) is back in focus after completing enrollment ahead of schedule in its Phase 2 ANKTIVA bladder cancer trial. Interim data show statistically significant response durability compared with BCG alone and no significant safety concerns. See our latest analysis for ImmunityBio. The latest ANKTIVA trial update arrives after a significant 3-month share price return of about 3.7x and a 416.83% year-to-date share price return, alongside a 245.70% 1-year total shareholder return. This...

Moody’s Corporation recently reported higher fourth-quarter and full-year 2025 results, continued its share repurchase program, filed a shelf registration for new debt securities, and earlier in February opened a new regional headquarters in Riyadh to deepen its presence in Saudi Arabia and the wider Middle East. Together, stronger earnings and the Riyadh regional hub highlight how Moody’s is pairing profit growth with a broader international footprint in a key capital‑markets region. We’ll...

NVR recently reported its fourth-quarter 2025 results, with earnings and Homebuilding revenue coming in ahead of consensus estimates despite weaker housing demand and affordability pressures. An interesting wrinkle is that, even with this earnings beat, analyst estimates for NVR have generally moved lower, pointing to a more cautious outlook on future performance. Next, we will examine how beating expectations amid softer housing demand shapes NVR's investment narrative for investors...

Synopsys (NasdaqGS:SNPS) has appointed former Deloitte executive Peter A. Shimer to its board of directors and Audit Committee. Shimer brings long-tenured leadership experience and involvement in AI-driven cancer research to Synopsys' governance bench. Separately, Innatera has selected Synopsys tools for design validation of neuromorphic edge AI microcontrollers used at the sensor level. Synopsys, trading at $424.66, sits at the intersection of chip design tools and AI-centric computing,...

uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term...

If you are wondering whether NBT Bancorp is reasonably priced or offering a margin of safety at its current US$42.78 share price, you are in the right place to get a clear, valuation focused view. The stock has slipped 2.0% over the last week and 3.7% over the last month, while still showing a 2.9% return year to date and longer term returns of 21.9% over 3 years and 22.7% over 5 years. These movements may signal shifting views on both its potential and its risks. Recent coverage of regional...

United States Antimony (UAMY) has stepped into the spotlight after back to back appearances at the BMO Global Metals, Mining & Critical Minerals Conference and PDAC 2026, supported by fresh investor materials on its integrated North American platform. See our latest analysis for United States Antimony. The recent conference appearances and supply chain updates come against a backdrop of strong momentum, with a 90 day share price return close to 99% and a very large 1 year total shareholder...

LXP Industrial Trust (LXP) has put fresh numbers in front of investors with its Q4 2025 investor presentation, spotlighting 97.1% portfolio occupancy and a new approximately 1 million square foot Phoenix development tied to strong industrial demand. See our latest analysis for LXP Industrial Trust. At a share price of $49.09, LXP Industrial Trust has seen a 15.53% 1 year total shareholder return, even though its year to date share price return is slightly negative and short term moves remain...